Q-omics provides the consensus-scored GPRIN3 profile across patient tissues and cancer cell-line models. GPRIN3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPRIN3 is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, GPRIN3 protein abundance shows 27,513 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, STAD, and LSCC as cancer lineages where GPRIN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPRIN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPRIN3 survival associations across molecular data types. GPRIN3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPRIN3 RNA expression–survival associations across cancer types. High GPRIN3 expression shows favorable associations in HNSC, KIRC, COAD, PAAD, SKCM and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GPRIN3 RNA expression.
This table summarizes GPRIN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in STAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GPRIN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPRIN3 shows lower tumor expression in LUSC and LUAD and higher tumor expression in STAD, KICH, HNSC and CHOL. The STAD box plot shows higher GPRIN3 RNA expression in tumor versus normal tissue (log2 FC = +1.374, t-test p < 0.001).
This table shows molecular features associated with GPRIN3 in patient tissues and cancer cell lines. In patient samples, GPRIN3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPRIN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
